Immune Therapeutics Inc (IMUN) 0.1680 $IMUN Lodonal(TM)

Immune Therapeutics Inc (IMUN) 0.1680 $IMUN

Lodonal(TM) Expected to Receive International Exposure at the World Health Assembly, one of the World's Leading Health Forums
PR Newswire - Thu May 19, 8:30AM CDT
Immune Therapeutics, Inc. (O

Immune Therapeutics, Inc. Provides Drug Development Program Status Update on Methionine-Enkelphine ("MENK" in China
PR Newswire - Mon Apr 11, 8:54AM CDT
Immune Therapeutics, Inc. (OTCQB: IMUN); a clinical-stage international biotechnology company providing immunotherapy solutions for the treatment of diseases, autoimmune diseases, and cancer, announced today it is providing shareholders with a status update of Immune Therapeutics, Inc.'s (IMUN) drug development program in China with long-term partner Hubei Qianjiang Pharmaceutical Co. Ltd (Qianjiang).

Immune Therapeutics, Inc. Announced the Completion of the Bridging Trial
ACCESSWIRE - Thu Jan 21, 8:45AM CST
Company Also Announced the Submission of Lodonal(TM) Data for Review in Connection with the New Drug Application to NAFDAC for Use as an Immune Booster and Adjunct Treatment for Human Immunodeficiency Virus

Immune Therapeutics, Inc., announced the completion of the bridging trial and submission of Lodonal(TM)
ACCESSWIRE - Thu Jan 21, 5:00AM CST
Data for review in connection with the New Drug Application to NAFDAC for use as an immune booster and adjunct treatment for Human Immunodeficiency Virus

Immune Therapeutics Inc. To Present at JP Morgan Health Conference
ACCESSWIRE - Mon Jan 11, 2:30PM CST
ORLANDO, FL / ACCESSWIRE / January 11, 2016 / Immune Therapeutics Inc. (OTCQB: IMUN) CEO, Noreen Griffin, will be making a presentation at today's JP Morgan Health Conference at the Fairmont hotel in San Francisco.

Immune Therapeutics Inc. Provides Update on Clinical Trial of Lodonal as an Immune-System Regulating Agent in Subjects with Compromised Immune Systems
ACCESSWIRE - Wed Oct 07, 5:21PM CDT
ORLANDO, FL / ACCESSWIRE / October 7, 2015 / Immune Therapeutics Inc. a specialty biopharmaceutical company (OTCQB: IMUN) today provided an update on the ongoing clinical trial of Lodonal in Nigeria.

Immune Therapeutics Adds Experienced New Board Member Saiid Zarrabian
ACCESSWIRE - Wed Oct 07, 5:18PM CDT
ORLANDO, FL / ACCESSWIRE / October 7, 2015 / Immune Therapeutics, Inc., a U.S. public company (OTCQB: IMUN), announces the appointment of Saiid Zarrabian as Immune's newest board member.
SNMX: 2.42 (-0.04)

Immune Therapeutics Inc, and ARAH Pharma Granted License to Import Lodonal to Nigeria
ACCESSWIRE - Wed Aug 12, 1:05PM CDT
To Be Used As an Adjunct Treatment for HIV/AIDS and Opportunistic Infections by Nigerian National Agency for Food and Drug Administration and Control

Immune Therapeutics Inc. in partnership with GB Pharma and AHAR sign LOI with Fidson Healthcare Plc for the distribution of Lodonal in Nigeria.
GlobeNewswire - Mon Aug 03, 8:27AM CDT
via PRWEB - An agreement between Immune Therapeutics GB Pharma/AHAR with Fidson Healthcare will enable Fidson marketing, sales, customer support, and technical assistance organization to promote LodonalTM in Nigeria. This will elevate Immune Therapeutics and GB Pharma/AHAR distribution network to the next level. The distribution will become effective, upon completion of the ongoing NAFDAC approved 90‐day Bridging trial evaluating the efficacy and safety of LodonalTM.

ClearTrust, LLC is Immune Therapeutics' New Transfer Agent and Support Provider
PR Newswire - Mon Jan 26, 2:44PM CST
Dear Immune Therapeutics, Inc. (OTC-BB: IMUN) Shareholder:

Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc.
PR Newswire - Fri Jan 23, 2:15PM CST
Immune Therapeutics, Inc. (OTC-BB: IMUN) today announced the signing of the agreement with KRS Global Biotechnology, Inc. for the compounding, packaging and distributing of its naltrexone tablets. The tablets will be compounded for shipment in the United States.

Immune Therapeutics, Inc. Announces Appointment of New Director and Acceptance of Election by Director
PR Newswire - Wed Jan 21, 9:00AM CST
Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the manufacture, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system, today announced that Vincent Butta, a new director appointed to fill a vacancy, and Edward Teraskiewicz, a director elected at the 2014 Annual Meeting of Shareholders, joined the Board on January 13, 2015.

Immune Therapeutics Inc. Announces Appointment of New President and Chief Operating Officer
PR Newswire - Wed Jan 14, 10:01AM CST
Immune Therapeutics Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the manufacture, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system, today announced the appointment of Seth Elliot as President and Chief Operating Officer.

The Jack Brewer Foundation and Immune Therapeutics Inc. Announce Medical Equipment Donation Program for the Prevention of Cervical Cancer in Africa to be Unveiled Today at the United Nations
PR Newswire - Thu Jan 08, 9:00AM CST
Immune Therapeutics Inc. (OTC:BB IMUN) - The Jack Brewer Foundation (JBF Worldwide) and Immune Therapeutics, Inc. announced today a first-of-its-kind donation program to improve access to treatment to prevent cervical cancer that until now has been unavailable to the women of Malawi, Africa.